INS and metabolic dysfunction-associated steatotic liver disease: The administration of OCA (25, 50 mg/day per os during 6 weeks) in patients with type two diabetes mellitus and NAFLD significantly reduced body weight, improved insulin sensitivity and reduced serum level of gamma-glutamyltransferase, whereas increase in serum FGF-19 intestinal enterokine confirmed the activation of FXR in the patients (Mudaliar et al., 2013).